Health-related quality of life in patients surviving non-small cell lung cancer

Janneke P. C. Grutters*, Manuela A. Joore, Erwin M. Wiegman, Johannes A. Langendijk, Dirk de Ruysscher, Monique Hochstenbag, Anita Botterweck, Philippe Lambin, Madelon Pijls-Johannesma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

70 Citations (Scopus)


Background and aims The EuroQol 5D (EQ-5D) is a standardised instrument for measuring health-related quality of life (HRQoL). It provides a utility score for health, and a self-rating of HRQoL (EQ-VAS). In this study, the EQ-5D was used to assess HRQoL in survivors of non-small cell lung cancer (NSCLC). The influence of tumour stage, adverse events, initial treatment and presence of recurrence was examined.

Methods Patients treated for NSCLC were sent a questionnaire, consisting of the EQ-5D, EQ-VAS and questions regarding adverse events. Tumour stage, date and type of initial treatment, and presence of recurrence were derived from patient files once patients had completed the questionnaire and informed consent form. Influencing factors were examined by exploring subgroups and using multiple regression analysis.

Results Of the 374 patients contacted, 260 (70%) returned a completed questionnaire. The EQ-VAS generated an average self-rated health of 69 (SD 18). The mean utility score was 0.74 (SD 0.27). Respondents with severe adverse events (dyspnoea grade >= 3) had statistically significantly lower utility scores than respondents without severe adverse events (median 0.52 vs 0.81; p

Conclusion The results of the present study provide original data on HRQoL during survival of NSCLC. Adverse events were found to have a considerable impact on HRQoL. This stresses the need to search for treatment modalities that not only improve survival, but also reduce adverse events.

Original languageEnglish
Pages (from-to)903-907
Number of pages5
Issue number10
Publication statusPublished - Oct-2010


  • CARE
  • COST

Cite this